Cend Therapeutics

Delivering more effective  anticancer drugs

The leading platform for targeted drug delivery

Effectively treating solid tumor cancers

Cend Therapeutics is a clinical-stage biotech company focused on a novel approach to provide more effective treatments for solid tumor cancer patients.

About Us

Pancreatic

Breast

Gastric

OUR

PIPELINE

Liver

Lung

Brain

Learn More

Latest News

August 10, 2022

Cend Therapeutics and Prospective Merger Partner Caladrius Biosciences Announce Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer

OUR

SCIENCE

PARTNERS AND
INVESTORS

Cend and our investors are committed to delivering better therapies for a range of solid tumor cancer patients. We work with partners who are leaders in their fields to help them better address cancers for the patients they serve.

On September 15, 2022, Caladrius Biosciences and Cend Therapeutics announced the closing of their merger. The merged company will now operate as Lisata Therapeutics, Inc. and will commence trading on The Nasdaq Capital Market under the ticker symbol “LSTA”.

Press Release Announcement

Lisata’s Corporate Presentation

Lisata’s new corporate website is still under construction.
Please visit Caladrius’ website for more information.